Jordi Bruix
乔迪·布鲁伊克斯
MD, PhD
Director, Barcelona Clinic Liver Cancer (BCLC) Group巴塞罗那临床肝癌（BCLC）研究组主任
👥Biography 个人简介
Jordi Bruix created the Barcelona Clinic Liver Cancer (BCLC) staging system, now the global standard for HCC management. He co-led the sorafenib SHARP trial and the regorafenib RESORCE trial, shaping international HCC treatment guidelines for two decades.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
BCLC Staging System
Developed and continuously updated the BCLC staging and treatment allocation system, adopted by EASL and AASLD as the standard framework for HCC management globally.
Systemic Therapy Trials
Principal investigator on SHARP (sorafenib) and RESORCE (regorafenib) trials, establishing first- and second-line systemic therapy standards for advanced HCC.
Representative Works 代表性著作
Regorafenib for Patients with Hepatocellular Carcinoma Who Progressed on Sorafenib (RESORCE)
Lancet (2017)
Established regorafenib as the first second-line systemic therapy improving OS in sorafenib-progressed HCC.
EASL Clinical Practice Guidelines: Management of Hepatocellular Carcinoma
Journal of Hepatology (2018)
Comprehensive HCC management guidelines incorporating BCLC staging; widely used across European and global centers.
🏆Awards & Recognition 奖项与荣誉
📄Data Sources 数据来源
Last updated: 2026-01-15 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Drew M. Pardoll
Johns Hopkins University
Padmanee Sharma
MD Anderson Cancer Center
Naiyer A. Rizvi
Columbia University Irving Medical Center
关注 乔迪·布鲁伊克斯 的研究动态
Follow Jordi Bruix's research updates
留下邮箱，当我们发布与 Jordi Bruix（Hospital Clínic de Barcelona, University of Barcelona）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment